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Abstract
Background: Two TB control strategies appropriate for South Asia (a community-based DOTS
[CBD] strategy and a family-based DOTS [FBD] strategy) have been shown to be effective in Nepal
in meeting the global target for the proportion of registered patients successfully treated. Here we
estimate the costs and cost-effectiveness of the two strategies. This information is essential to
allow meaningful comparisons between these and other strategies and will contribute to the small
but growing body of knowledge on the costs and cost-effectiveness of different approaches to TB
control.
Methods: In 2001–2, costs relating to TB diagnosis and care were collected for each strategy.
Structured and semi-structured questionnaires were used to collect costs from health facility
records and a sample of 10 patients in each of 10 districts, 3 using CBD and 2 using FBD. The data
collected included costs to the health care system and social costs (including opportunity costs)
incurred by patients and their supervisors. The cost-effectiveness of each strategy was estimated.
Results: Total recurrent costs per patient using the CBD and FBD strategies were US$76.2 and
US$84.1 respectively. The social costs incurred by patients and their supervisors represent more
than a third of total recurrent costs under each strategy (37% and 35% respectively). The CBD
strategy was more cost-effective than the FBD strategy: recurrent costs per successful treatment
were US$91.8 and US$102.2 respectively.
Discussion: Although the CBD strategy was more cost-effective than the FBD strategy in the
study context, the estimates of cost-effectiveness were sensitive to relatively small changes in
underlying costs and treatment outcomes. Even using these relatively patient-friendly approaches
to DOTS, social costs can represent a significant financial burden for TB patients.
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Tuberculosis is a leading cause of death worldwide [1],
South Asia being the worst affected region in terms of
absolute numbers [2]. The internationally recommended
DOTS strategy for TB control [3,4] has been successfully
implemented in the public sector by many National
Tuberculosis Programmes (NTPs) and there have been
recent attempts to estimate the economic benefit of TB
control at the international level [5]. A major element of
the strategy is Direct Observation of Treatment (DOT), in
which a health worker or someone responsible to the
health system observes the patient swallowing each dose
of treatment for at least the first 2 months of treatment
(and preferably gives encouragement and support). In
recent years there has been increasing awareness of the
need to estimate the cost implications of various
approaches to implementing DOTS [6-13]. This need is
emphasised by the recent move to more flexible supervi-
sion and patient support within the new Stop TB strategy
[14] and the International Standards for Tuberculosis
Care (ISTC) [15].
In Nepal, over 14,000 new cases of smear positive (i.e.
infectious) tuberculosis are notified each year [16]. Many
patients in the so-called hill and mountain districts live far
from the nearest health facility, so that access to daily
DOT at a health facility is not feasible. To address this
problem, two strategies – community-based DOTS and
family-based DOTS – were developed and assessed in 10
districts using a district-randomised controlled trial
(RCT), with each strategy being randomly assigned to 5
districts [17,18]. The only difference between the two
strategies was the observation component, which com-
prises supervision by a community health volunteer or a
family member respectively.
In the RCT, the treatment success rates of the CBD and
FBD strategies were 85% and 89% respectively [18]. Both
strategies have met the international target of 85% treat-
ment success rate, and there was no significant difference
between the outcomes of the two strategies. A detailed
description of each strategy and the outcomes are pub-
lished elsewhere [18]. The objective of this paper is to
report the costs and cost-effectiveness of the two DOTS
schemes in order to contribute to the future planning of
TB control services in developing countries. It was impor-
tant to assess not only health systems costs, but also those
of patients, since with an average per capita income of
US$378 [19], many patients in Nepal experience financial
constraints to accessing TB treatment.
Methods
Costing was undertaken in five districts of Nepal, namely
Palpa, Syangja, Doti, Baglung and Dolakha. The first three
implemented the CBD strategy and the remaining two the
FBD strategy. The findings from Palpa district are dis-
cussed separately, as the district TB control programme in
Palpa was supported by an NGO (United Mission to
Nepal Tansen Hospital), which may have affected the
study results.
The study used a comprehensive approach to estimating
costs and cost-effectiveness, to allow a more holistic
assessment of the long-term sustainability of the different
strategies [20,21]. The data collected included not only
costs to the health care system and direct costs to patients
and their treatment supervisors but also social costs i.e.
other costs (including opportunity costs) incurred by
patients and supervisors. Analysis was initially planned to
focus primarily on costs to the health system and include
social costs for comparison purposes only. It was later
decided to use sensitivity analysis on a model of total
costs (including health systems and social costs) to better
understand the study results.
The data for this study were collected in 2001–2002. All
costing data was collected in Nepali Rupees (NRs) and
then converted into US$ at the official exchange rate of the
National Bank of Nepal for 2000–2001 of 1US$ =
74.65NRs.
Both start-up and recurrent costs were obtained. Start-up
costs (primarily training and communication) were col-
lected from health facilities using a structured question-
naire. Recurrent (ongoing) costs were collected across two
main categories: costs to the health system and social
costs. The costs to the health system were gathered from
district health facilities' financial records using a struc-
tured proforma. Social costs (costs to the patients and
their supervisors) were collected using semi-structured
questionnaires. A sample of 50 patients (10 from each dis-
trict) and their treatment supervisors was used. In each
district, these 10 patients were selected randomly from
patients under treatment during the period planned for
data collection, using the district TB treatment register.
Only patients who had completed the intensive phase of
treatment (generally 2 months) and one month of the
continuation phase of treatment were included, to ensure
a wide coverage of costs.
In the analysis of recurrent costs, health system-related
costs were allocated to six broad types, namely staff sala-
ries, training (including monitoring and supervision),
medicines, transportation, utilities and others (supplies,
logistics, social mobilisation through DOTS committees),
and to five levels: national, regional, district, treatment
centre and treatment sub-centre. At each level only costs
attributed to the organisation and management of the
DOTS scheme were included. We also report start-up costsPage 2 of 8
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such strategies.
Social costs were divided into those incurred directly by
patients themselves and costs incurred by their treatment
supervisors (community members in the CBD strategy
and family members in the FBD strategy). Measures to
minimise recall bias by patients and their supervisors
included triangulation of data between patients and their
treatment supervisors, triangulation methods applied
during interviews, and informal discussion with local
health care providers and community gate-keepers, to
confirm details such as travel distances and number of vis-
its to treatment centres. The social costs considered in this
study included direct costs, opportunity costs and other
(miscellaneous) expenses. Opportunity costs of time lost
by patients and their supervisors were estimated as the
actual time (in days) lost due to TB by patients and their
supervisors for travel to health facility and for visits to the
treatment supervisor/patient. The focus of this study was
on costs of seeking treatment for TB and not on the eco-
nomic impact of TB itself; therefore opportunity costs did
not include the time lost due to patients being too ill to
work.
A more detailed description of cost identification meth-
ods for each type of cost is given in Table 1.
Table 1: Methods of identification of costs in the study
Costs Notes Identification method Source of data
Health Systems costs
Staff salaries Includes only the proportion of annual 
salary of staff attributable to TB
Salary rate for this category of staff (net 
salary per day) × annual days attributable 
to TB
Facility financial records
Semi-structured questionnaire
Training Includes monitoring and supervision Cost of training for this intervention as a 
proportion of the total cost of training for 
each facility number of training courses in 
the study sites (for regional level)
Facility records
Semi-structured questionnaire
Medicines NTP estimates of medicine costs per 
patient × Total number of patients in the 
study sites
Tuberculosis Control in Nepal 
2055–2060 (1998–2003), Long Term 
Plan;
Annual Report of TB Control 
Program Nepal, 2058/2059 
(2001/2002)
Facility records (for No of patients)
Transportation Includes transportation of medicines 
and laboratory supplies.
Total cost of transportation Facility records
Utilities Total cost of utilities × time for TB 
programme (e.g. 1/3 for regional level)
Facility records
Semi-structured questionnaire
Others Includes supplies, logistics, social 
mobilisation through DOTS 
committees
Facility records
Semi-structured questionnaire
Social costs
Direct costs Includes treatment and travel charges Number of visits × travel and consultation 
charges
Semi-structured questionnaire
Opportunity costs Includes costs for time lost due to 
involvement in the scheme
Standardised daily rate for unskilled labour 
(NRs 85/day) × time lost due to 
involvement in the scheme
Semi-structured questionnaire
Other costs Includes miscellaneous expenses such 
as refreshments while in the treatment 
centre
Patients and supervisors' recollection of 
any other expenses
Semi-structured questionnairePage 3 of 8
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registered and then scaled up to the actual numbers of TB
patients enrolled for treatment in each district according
to NTP records (Table 2). Medians of costs were used
when estimating social costs per patient as they are more
representative of skewed data than means, especially
when analysing small samples [9].
The effectiveness of each scheme was estimated using the
number of patients for whom the treatment was success-
ful [7]. To estimate cost-effectiveness, only recurrent costs
were used, as we were primarily interested in assessing the
long-term sustainability of the schemes although we rec-
ognise the limitations of excluding start-up costs, particu-
larly in assessing the short-term cost implications of the
scheme.
A sensitivity analysis of cost-effectiveness was performed
to determine how the cost-effectiveness was sensitive to
variations in the costs per patient and treatment success
rates.
Results
In the 5 districts used in the economic study, the total
numbers of new sputum smear positive TB patients regis-
tered in the districts implementing the CBD and FBD
strategies were 460 and 253 respectively. The total num-
bers of patients who were successfully treated were 382
and 208 respectively, giving treatment success rates of
83% and 82% respectively. A detailed breakdown of costs
per patient is given in Table 3.
Total recurrent costs per patient were lower using CBD
(US$76.2) than using FBD (US$84.1). In both CBD and
FBD, social costs incurred by patients and their supervi-
sors represented more than a third of total recurrent costs
(37% in CBD and 35% in FBD).
Most health system-related costs were salaries (53% and
47% of total health system-related costs in CBD and FBD
respectively) and medicines (26% and 24% respectively).
A separate analysis of health system costs by programme
level showed that about half the costs were incurred at the
national level (US$22.3 and US$24.6 per patient in CBD
and FBD respectively). The breakdown of health system-
related costs by level (Table 4) shows the dominance of
health systems-related costs at the national level (46%
and 45% of total costs respectively) followed by district-
level costs (32% and 16% respectively).
Patients' costs comprised the largest share of social costs
(89% and 69% in CBD and FBD respectively). The major-
ity of patients' costs were the opportunity costs of time
lost due to seeking treatment for TB (46% and 79%
respectively) followed by direct costs (29% and 21%
respectively) and other costs (24% in CBD only). Like-
wise, most supervisors' costs were opportunity costs (73%
and 84% respectively).
Start-up costs per patient registered were estimated as
US$20 under the CBD strategy and US$31.7 under the
FBD strategy.
The cost-effectiveness of the two strategies is given in
Table 5. The total recurrent costs per case successfully
treated were lower using CBD than using FBD. Health sys-
tem-related costs dominated in both strategies (64%
using CBD and 65% using FBD) with patient-related costs
comprising most of the social costs (90% using CBD and
69% using FBD).
Unexpectedly, the costs and cost-effectiveness estimated
for Palpa district were found to be lower than in the other
two districts using the CBD strategy (Tables 3 and 5). This
may be due to the different accounting systems and the
subsidised structure of the TB treatment costs occurring in
Palpa, a mission hospital.
The effect of changes in costs per patient and treatment
success rates in the CBD strategy on the balance of cost-
effectiveness between CBD and FBD strategies is shown in
Figure 1. Results of modelling of costs showed that a
change of about 12% in either costs per patient treated or
in the treatment success rate in one strategy can poten-
tially shift the balance of cost-effectiveness between the
CBD and FBD strategies.
Discussion
The study results show that for both strategies, social costs
make up more than a third of total costs. This fits with our
Table 2: Numbers of patients in each study district [18]
Districts using community-based DOTS strategy Districts using family-based DOTS strategy
Palpa Syangja Doti Total* Baglung Dolakha Total
Total no of patients treated, including: 422 335 125 460 136 117 253
No of patients successfully treated 367 276 106 382 104 104 208
* Total of Syangja and DotiPage 4 of 8
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costs and direct (travel) costs are dependent on the dis-
tance between the patient and treatment supervisor, and is
in line with findings from a study conducted in Bangla-
desh which found facility-based DOTS to be more expen-
sive than a strategy involving Community Health Workers
[22]. Thus, even though TB treatment is highly cost-effec-
tive, it can represent a considerable financial burden to
patients, particularly economically disadvantaged groups.
This finding is consistent with those from studies else-
where [7,9,11].
We found that the CBD strategy was more cost-effective
than the FBD strategy: recurrent costs per successful treat-
ment were lower. This is in contrast to findings in Pakistan
where family-based DOTS was found to be more cost-
effective than a health centre/community-based scheme
[8]. One explanation might be that CBD treatment success
rates are higher. However, sensitivity analysis reveals that
a change of 12% in either total costs per patient or a treat-
ment success rate in either CBD or FBD strategy may shift
the balance of cost-effectiveness between the strategies
and make the FBD strategy more cost-effective.
Table 3: Costs incurred in the districts using the community-based DOTS strategy and the family-based DOTS strategy (US$)
Districts using the community-based DOTS strategy Districts using the family-based DOTS strategy
Palpa Syangja Doti Total* Baglung Dolakha Total
Total number of patients treated 422 335 125 460 136 117 253
No of patients successfully treated 367 276 106 382 104 104 208
Treatment success rate 87% 82% 85% 83% 76% 89% 82%
Costs per patient
Total recurrent costs, including: 65.7 71.4 89.3 76.2 85.4 82.5 84.1
Recurrent cost to health system 42.0 42.7 62.5 48.1 59.2 48.6 54.3
Personnel costs 19.9 21.5 35.6 25.3 26.6 23.9 25.3
Drug costs 12.5 12.1 12.9 12.3 13.0 12.9 13.0
Transportation 0.9 1.1 6.8 2.7 5.1 3.2 4.2
Utilities 3.7 4.6 2.8 4.1 6.3 5.3 5.9
Training, supervision, monitoring 1.6 1.8 4.0 2.4 2.3 1.9 2.1
Others 
(supplies, logistics, social mobilisation)
3.5 1.6 0.5 1.3 5.9 1.4 3.8
Recurrent cost to patients and 
supervisors
23.6 28.6 26.8 28.1 26.2 34.0 29.8
Total costs to patients: 20.7 25.2 24.4 25.0 21.6 19.2 20.5
Opportunity costs 13.4 12.5 9.2 11.6 13.4 19.2 16.1
Direct costs 5.1 6.9 8.6 7.3 8.2 0.0 4.4
Other costs 2.2 5.8 6.6 6.1 0.0 0.0 0.0
Total costs to supervisors, including: 3.0 3.4 2.3 3.1 4.6 14.7 9.3
Opportunity costs 3.0 2.3 2.3 2.3 2.8 13.6 7.8
Direct costs 0.0 1.1 0.0 0.8 2.5 0.2 1.4
* Total of Syangja and Doti
Table 4: Breakdown of health system-related costs by level (US$)
Districts using the community-based DOTS strategy Districts using the family-based DOTS strategy
Level Palpa Syangja Doti Total* Baglung Dolakha Total
Total, including 17,740.8 14,320.1 7,817.0 22,137.1 8,045.2 5,684.3 13,729.5
National 8,894.3 7,655.1 2,583.2 10,238.3 3,590.2 2,623.3 6,213.6
Regional 2,433.7 2,433.7 1,002.5 3,436.1 1,223.2 22.8 1,246.0
District 1,926.7 1,573.7 1,940.4 3,514.0 2,551.6 1,781.2 4,332.7
Treatment centre 3,904.7 1,324.8 1,149.7 2,474.5 431.1 903.0 1,334.1
Treatment sub-centre 581.4 1,332.8 1,141.3 2,474.2 249.0 354.0 603.0
* Total of Syangja and DotiPage 5 of 8
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cost-effectiveness, as the primary focus of this study is to
assess the economic sustainability of the two approaches
in the long term. We recognise, however, that start-up
costs are also important, particularly to the health system.
For example, the cost-effectiveness of developing similar
initiatives elsewhere would depend on the availability of
health staff at nearby health facilities (who will shoulder
additional responsibilities associated with community-
based initiatives).
Health systems costs per successful treatment under the
CBD strategy were lower than under the FBD strategy.
Similar results were found with start-up costs. These find-
ings suggest that that FBD schemes are more expensive to
establish and are likely to require larger recurrent
resources from the health system than community-based
schemes in the long-term. Start-up costs in the CBD strat-
egy are effectively fixed costs and as such are unlikely to be
very sensitive to the number of patients treated. On the
contrary, start-up costs in the FBD scheme will generally
be correlated with the number of patients.
An analysis of health systems costs by level showed a sig-
nificant share of the costs was incurred at the national
level. This indicates that budget absorption at the national
level is high even in decentralised service delivery strate-
gies such as CBD and FBD. We consider this an important
finding, particularly when considering service delivery
Table 5: Cost-effectiveness of the community-based DOTS strategy and the family-based DOTS strategy (US$)
Community-based DOTS strategy Family-based DOTS strategy
Palpa Syangja Doti Total* Baglung Dolakha Total
Recurrent costs per treatment succeeded, including 75.5 86.6 105.3 91.8 111.6 92.9 102.2
Total recurrent cost to health system per treatment succeeded 48.3 51.9 73.7 58.0 77.4 54.7 66.0
Total recurrent social costs (patients + supervisors) per treatment 
succeeded including:
27.2 34.7 31.6 33.9 34.3 38.2 36.2
Total costs to patients per treatment succeeded 23.8 30.6 28.8 30.1 28.3 21.7 25.0
Total costs to supervisors per treatment succeeded 3.4 4.1 2.7 3.7 6.0 16.5 11.3
* Total of Syangja and Doti
Effect of changes in treatment success rates and costs per patient registered on the cost-effectiveness of the family-based DOTS and community-bas d DOTS t giesFigure 1
Effect of changes in treatment success rates and costs per patient registered on the cost-effectiveness of the 
family-based DOTS and community-based DOTS strategies. The figure presents the effect of changes in the treat-
ment success rates (%) and costs per patient (US$) under the CBD strategy on the balance of cost-effectiveness between the 
FBD and CBD strategies. Note: The axes cross at the current treatment success rate (83%) and costs per patient (US$76.2) 
for the community-based DOTS strategy.
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financial burden to programmes at the national level.
Analysis of social costs per successful treatment reveals
marginally lower costs for the CBD strategy than for the
FBD strategy, supporting an earlier conclusion that it is
more cost-effective to administer DOTS through commu-
nity-based schemes. It is worth noting that these results
are generally consistent with the difference in costs
incurred by the health system. Within each arm, overall
costs incurred by patients represent the largest share of
overall social costs – an important finding if cost-minimi-
sation strategies for economically disadvantaged popula-
tions are to be explored.
An unexpected finding is that the cost per successful treat-
ment to family member treatment supervisors ($11.3) is
three times that of community volunteer supervisors
($3.7). This is however mirrored by the finding that costs
per successful treatment to patients on the FBD strategy
($25.0) are lower than those on the CBD strategy ($30.1)
(Table 5). This almost certainly reflects a transfer of costs
involved in travel to collect drugs, which in the family
member strategy fall on the family member supervisor,
and in the community strategy fall on the patient. It is
important to note, however, that under the family mem-
ber strategy, both patient and family member supervisor
costs fall on the patient's family.
If the choice between CBD and FBD is guided by measures
of cost-effectiveness, based on our study, we would rec-
ommend the CBD strategy. However, cost-effectiveness is
by no means the only criterion for making any planning
and policy decisions on TB control. Other criteria for such
decisions may include the following:
• social acceptability of particular initiatives, e.g. willing-
ness of patients to overcome possible cultural barriers in
approaching a community member in order to request
supervision of DOTS;
• availability of community member supervisors, as well
as their attitude and willingness to monitor the treatment
of TB patients;
• availability of robust supply and logistics mechanisms
within the health system to ensure timely and continuous
provision of DOTS medicines to patients/treatment super-
visors;
• other health system- and social-related issues that are
pertinent to different contexts such as the degree of decen-
tralisation, or cultural norms which may facilitate or
inhibit the implementation of decentralised DOTS
schemes.
Conclusion
The study found that the CBD strategy was more cost-
effective than the FBD strategy in the context of the study
districts of Nepal. However, cost-effectiveness was sensi-
tive to relatively small changes in underlying costs and
treatment outcomes. DOT at both community and family
levels achieves high clinical outcomes (over 80%) at rela-
tively low costs per successful treatment and both strate-
gies or variants thereof are worthy of consideration by
NTPs contemplating moving towards more patient-
friendly supervision and patient support as recommended
in the new Stop TB strategy [14] and the ISTC [15].
Social costs can represent a significant financial burden
for TB patients, particularly if they are already poor. Cost-
minimisation strategies should include consideration of
social costs, to avoid situations where cost reductions
merely shift costs from NTPs to patients. On the other
hand, it is important to recognise the burden to the health
system at the national level when planning decentralised
strategies such as one assessed here.
Finally, despite the growing number of publications on
the topic, further research using a consistent costing
framework is needed to assess cost-effectiveness of similar
forms of DOT (CBD and FBD) in other contexts as well as
other forms of TB care (eg. self-administered treatment).
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